|
May 25
|
1 Stock Down 97% That Could Double, According to Wall Street
|
|
May 15
|
A new CFO tasked with taking ‘scrappy’ Editas from last year’s layoffs into new gene editing territory
|
|
May 14
|
Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June
|
|
May 14
|
Editas Medicine First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
|
|
May 14
|
Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas’ Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting
|
|
May 13
|
Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year?
|
|
May 13
|
Editas Q1 Loss Narrower Than Expected, Revenues Increase Y/Y
|
|
May 13
|
Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting
|
|
May 12
|
Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates
|
|
May 12
|
Editas: Q1 Earnings Snapshot
|
|
May 12
|
Editas Medicine Announces First Quarter 2025 Results and Business Updates
|
|
May 12
|
Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board
|
|
May 12
|
Editas (EDIT) Upgraded to Buy: What Does It Mean for the Stock?
|
|
Apr 23
|
Editas Medicine, Inc. (NASDAQ:EDIT) institutional owners may be pleased with recent gains after 71% loss over the past year
|
|
Mar 13
|
Here's Why Editas Medicine (NASDAQ:EDIT) Must Use Its Cash Wisely
|
|
Feb 24
|
Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March
|
|
Feb 20
|
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
|
Dec 30
|
Why Is Editas Medicine, Inc. (EDIT) Among the Top CRISPR Stocks to Invest In?
|
|
Oct 5
|
Editas Medicine Secures $57M Deal for Gene-Editing Technology
|
|
Oct 4
|
Editas trades part of Vertex CRISPR therapy licencing rights deal for $57m
|